Athenecia Faggins of Minaris Advanced Therapies discusses raw material qualification, supplier management, testing, and risk control for advanced therapy manufacturing.
|Articles|December 14, 2017
Additional Size for Quaternary Diaphragm Pumps
Author(s)BioPharm International Editors
The Quattroflow QF10k size pump from PSG, a Dover company, has been added to its line of quaternary, four-piston diaphragm pumps.
Advertisement
PSG, a Dover company, has expanded its Quattroflow line of quaternary, four-piston diaphragm pumps to include the QF10k size pump. The pump has been designed to fill the gap between the existing QF4400/5050 and QF20k pump sizes and provides a maximum flow rate of 10,000 lph.
Product features include a stainless-steel pump chamber design, a maximum pressure of 6 bar (87 psi), 20:1 turn-down ratio, linear flow performance, and high-flow stability even at low flow rates. Additionally, the pump offers clean-in-place/steaming-in-place and autoclave capabilities. Available accessories include control box, power box, diaphragm sensor, and proportional–integral–derivative controller. Typical applications include chromatography and cross-flow filter systems.
Source:
Advertisement
Related to this article
Panelists from FDA, Genentech, and Minaris discussed raw material risk, supplier oversight, and at-risk release strategies for advanced therapies at the PDA/FDA Joint Regulatory Conference.
Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.
FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.
Insilico's Longevity Vaccines use circular mRNA to arm T cells against aging's earliest culprit cells, starting with immune rejuvenation.
Tambotatug pelitecan (Tam-Peli), a B7-H3-targeted antibody-drug conjugate, is the second of at least three B7-H3-targeted ADCs to post positive late-stage data in relapsed small-cell lung cancer this year.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Phio's PH-762 posted a 70% response rate in skin cancer, supporting its FDA briefing package for a planned phase 2b trial.
Advertisement
Advertisement